Cargando…

The Synergistic Effect of Plasminogen Activator Inhibitor-1 (PAI-1) Polymorphisms and Metabolic Syndrome on Coronary Artery Disease in the Korean Population

The most common type of cardiovascular disease is coronary artery disease (CAD), in which a plaque builds up inside the coronary arteries that can lead to a complete blockage of blood flow to the heart, resulting in a heart attack. The CAD may be affected by various factors including age, gender, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Han Sung, Sung, Jung-Hoon, Ryu, Chang Soo, Lee, Jeong Yong, Ko, Eun Ju, Kim, In Jai, Kim, Nam Keun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711432/
https://www.ncbi.nlm.nih.gov/pubmed/33260749
http://dx.doi.org/10.3390/jpm10040257
_version_ 1783618144843071488
author Park, Han Sung
Sung, Jung-Hoon
Ryu, Chang Soo
Lee, Jeong Yong
Ko, Eun Ju
Kim, In Jai
Kim, Nam Keun
author_facet Park, Han Sung
Sung, Jung-Hoon
Ryu, Chang Soo
Lee, Jeong Yong
Ko, Eun Ju
Kim, In Jai
Kim, Nam Keun
author_sort Park, Han Sung
collection PubMed
description The most common type of cardiovascular disease is coronary artery disease (CAD), in which a plaque builds up inside the coronary arteries that can lead to a complete blockage of blood flow to the heart, resulting in a heart attack. The CAD may be affected by various factors including age, gender, and lipoprotein disposition as well as genetic factors and metabolic syndrome. In this study, we investigated whether three PAI-1 polymorphisms (−844 G > A, −675 4G > 5G, and +43 G > A) and CAD-related clinical parameters are associated with CAD susceptibility. Genotyping of 463 CAD patients and 401 controls was performed using polymerase chain reaction restriction fragment length polymorphism analysis. We report that the 4G5G genotype (crude odds ratio(COR), 1.392; 95% confidence interval (CI), 1.036–1.871; p = 0.028) and dominant model (4G4G vs. 4G5G + 5G5G; COR, 1.401; 95% CI, 1.060–1.850; p = 0.018; adjust odds ratio, 1.371; 95% CI, 1.027–1.831; p = 0.032) of PAI-1 −675 polymorphisms were associated with increased CAD risk. Haplotype and genotype combinations of PAI-1 −675 and +43 polymorphisms show an increased risk of CAD according to alterations of the −675 polymorphism allele or genotype. Moreover, the PAI-1 -675 polymorphisms show a synergistic effect with the metabolic syndrome component of CAD risk. This study suggests that polymorphisms in the PAI-1 genes along with the metabolic syndrome component of CAD can be useful biomarkers for CAD diagnosis and treatment.
format Online
Article
Text
id pubmed-7711432
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77114322020-12-04 The Synergistic Effect of Plasminogen Activator Inhibitor-1 (PAI-1) Polymorphisms and Metabolic Syndrome on Coronary Artery Disease in the Korean Population Park, Han Sung Sung, Jung-Hoon Ryu, Chang Soo Lee, Jeong Yong Ko, Eun Ju Kim, In Jai Kim, Nam Keun J Pers Med Article The most common type of cardiovascular disease is coronary artery disease (CAD), in which a plaque builds up inside the coronary arteries that can lead to a complete blockage of blood flow to the heart, resulting in a heart attack. The CAD may be affected by various factors including age, gender, and lipoprotein disposition as well as genetic factors and metabolic syndrome. In this study, we investigated whether three PAI-1 polymorphisms (−844 G > A, −675 4G > 5G, and +43 G > A) and CAD-related clinical parameters are associated with CAD susceptibility. Genotyping of 463 CAD patients and 401 controls was performed using polymerase chain reaction restriction fragment length polymorphism analysis. We report that the 4G5G genotype (crude odds ratio(COR), 1.392; 95% confidence interval (CI), 1.036–1.871; p = 0.028) and dominant model (4G4G vs. 4G5G + 5G5G; COR, 1.401; 95% CI, 1.060–1.850; p = 0.018; adjust odds ratio, 1.371; 95% CI, 1.027–1.831; p = 0.032) of PAI-1 −675 polymorphisms were associated with increased CAD risk. Haplotype and genotype combinations of PAI-1 −675 and +43 polymorphisms show an increased risk of CAD according to alterations of the −675 polymorphism allele or genotype. Moreover, the PAI-1 -675 polymorphisms show a synergistic effect with the metabolic syndrome component of CAD risk. This study suggests that polymorphisms in the PAI-1 genes along with the metabolic syndrome component of CAD can be useful biomarkers for CAD diagnosis and treatment. MDPI 2020-11-28 /pmc/articles/PMC7711432/ /pubmed/33260749 http://dx.doi.org/10.3390/jpm10040257 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Park, Han Sung
Sung, Jung-Hoon
Ryu, Chang Soo
Lee, Jeong Yong
Ko, Eun Ju
Kim, In Jai
Kim, Nam Keun
The Synergistic Effect of Plasminogen Activator Inhibitor-1 (PAI-1) Polymorphisms and Metabolic Syndrome on Coronary Artery Disease in the Korean Population
title The Synergistic Effect of Plasminogen Activator Inhibitor-1 (PAI-1) Polymorphisms and Metabolic Syndrome on Coronary Artery Disease in the Korean Population
title_full The Synergistic Effect of Plasminogen Activator Inhibitor-1 (PAI-1) Polymorphisms and Metabolic Syndrome on Coronary Artery Disease in the Korean Population
title_fullStr The Synergistic Effect of Plasminogen Activator Inhibitor-1 (PAI-1) Polymorphisms and Metabolic Syndrome on Coronary Artery Disease in the Korean Population
title_full_unstemmed The Synergistic Effect of Plasminogen Activator Inhibitor-1 (PAI-1) Polymorphisms and Metabolic Syndrome on Coronary Artery Disease in the Korean Population
title_short The Synergistic Effect of Plasminogen Activator Inhibitor-1 (PAI-1) Polymorphisms and Metabolic Syndrome on Coronary Artery Disease in the Korean Population
title_sort synergistic effect of plasminogen activator inhibitor-1 (pai-1) polymorphisms and metabolic syndrome on coronary artery disease in the korean population
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711432/
https://www.ncbi.nlm.nih.gov/pubmed/33260749
http://dx.doi.org/10.3390/jpm10040257
work_keys_str_mv AT parkhansung thesynergisticeffectofplasminogenactivatorinhibitor1pai1polymorphismsandmetabolicsyndromeoncoronaryarterydiseaseinthekoreanpopulation
AT sungjunghoon thesynergisticeffectofplasminogenactivatorinhibitor1pai1polymorphismsandmetabolicsyndromeoncoronaryarterydiseaseinthekoreanpopulation
AT ryuchangsoo thesynergisticeffectofplasminogenactivatorinhibitor1pai1polymorphismsandmetabolicsyndromeoncoronaryarterydiseaseinthekoreanpopulation
AT leejeongyong thesynergisticeffectofplasminogenactivatorinhibitor1pai1polymorphismsandmetabolicsyndromeoncoronaryarterydiseaseinthekoreanpopulation
AT koeunju thesynergisticeffectofplasminogenactivatorinhibitor1pai1polymorphismsandmetabolicsyndromeoncoronaryarterydiseaseinthekoreanpopulation
AT kiminjai thesynergisticeffectofplasminogenactivatorinhibitor1pai1polymorphismsandmetabolicsyndromeoncoronaryarterydiseaseinthekoreanpopulation
AT kimnamkeun thesynergisticeffectofplasminogenactivatorinhibitor1pai1polymorphismsandmetabolicsyndromeoncoronaryarterydiseaseinthekoreanpopulation
AT parkhansung synergisticeffectofplasminogenactivatorinhibitor1pai1polymorphismsandmetabolicsyndromeoncoronaryarterydiseaseinthekoreanpopulation
AT sungjunghoon synergisticeffectofplasminogenactivatorinhibitor1pai1polymorphismsandmetabolicsyndromeoncoronaryarterydiseaseinthekoreanpopulation
AT ryuchangsoo synergisticeffectofplasminogenactivatorinhibitor1pai1polymorphismsandmetabolicsyndromeoncoronaryarterydiseaseinthekoreanpopulation
AT leejeongyong synergisticeffectofplasminogenactivatorinhibitor1pai1polymorphismsandmetabolicsyndromeoncoronaryarterydiseaseinthekoreanpopulation
AT koeunju synergisticeffectofplasminogenactivatorinhibitor1pai1polymorphismsandmetabolicsyndromeoncoronaryarterydiseaseinthekoreanpopulation
AT kiminjai synergisticeffectofplasminogenactivatorinhibitor1pai1polymorphismsandmetabolicsyndromeoncoronaryarterydiseaseinthekoreanpopulation
AT kimnamkeun synergisticeffectofplasminogenactivatorinhibitor1pai1polymorphismsandmetabolicsyndromeoncoronaryarterydiseaseinthekoreanpopulation